Basic Search  |  Summaries  |  Advanced Search

Violation Tracker UK Individual Case

Company: Cinven Capital Management (V) GP Ltd. and Cinven Partners LLP et al.
Current Parent CompanyCinven Group
Penalty: £4,856,620
Year: 2022
Date: 3 February, 2022
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.
Action Type: agency action
Agency: Competition and Markets Authority
HQ Country of Parent: United Kingdom
Ownership Structure of Parent: privately held
Major Industry of Parent: private equity (including portfolio companies)
Specific Industry of Parent: private equity (including portfolio companies)
Source of Data(click here)